The Wagoner County Sheriff's Office (WCSO) released body cam video of deputies responding to a diabetic driver who went off the roadway and crashed into a tree ...

Between 2019 and 2023, prescriptions for nasal spray formulations increased from 4% to 48%, those for glucagon autoinjectors increased by 18%, and those for unmixed syringes dipped from 96% to 31% ...

Glucagon is a recognised therapy for the disorder ... as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication.

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

People who use insulin or sulfonylurea medications to manage blood sugar should consider having a glucagon emergency kit on hand at all times. It’s a nasal spray or injection that treats severe ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 4 ...

Glucagon-like peptide-1 (GLP-1 ... Its flagship product, GIMOTI, is the only FDA-approved nasal spray for this condition, offering reliable absorption by bypassing the digestive system—a ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...